Targeting these receptors, to which the cancer cells have become addicted for survival, should block proliferation and either induce or sensitise the cells to apoptosis via the intrinsic pathway, thus providing the rational for using EGFR and Her2 in breast cancer therapy. The gene discussed is ERBB2; the disease is breast cancer.